Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) Could Achieve Gains In The Near Future

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Yahoo Finance discussed the stock recently as it posted New Data to be Presented for BioMarin’s VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

Biomarin Pharmaceutical Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Biomarin Pharmaceutical Inc. is $16.43B. A total of 0.62 million shares were traded on the day, compared to an average of 1.32M shares.

In the most recent transaction, Davis George Eric sold 24,602 shares of BMRN for 88.34 per share on Mar 28 ’24. After the transaction, the EVP, Chief Legal Officer now owns 55,856 company shares. In a previous transaction on Mar 06 ’24, BIENAIME JEAN JACQUES sold 1,000 shares at 86.71 per share. BMRN shares that Director owns now total 560,203.

Among the insiders who sold shares, FUCHS HENRY J disposed of 35,341 shares on Mar 05 ’24 at a per-share price of $85.18. This resulted in the President, Worldwide R&D holding 212,117 shares of BMRN after the transaction. In another insider transaction, Ajer Jeffrey Robert sold 4,000 shares at $87.07 per share on Mar 05 ’24. Company shares held by the EVP, Chief Commercial Officer now total 94,047.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, BMRN has a high of $100.38 and a low of $76.02.

As of this writing, BMRN has an earnings estimate of $0.33 per share for the current quarter. EPS was calculated based on a consensus of 17 estimates, with a high estimate of $0.49 per share and a lower estimate of $0.21. The company reported an EPS of $0.21 in the last quarter, which was -8.70% lower than expectations of $0.23.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. BMRN’s latest balance sheet shows that the firm has $1.01B in Cash & Short Term Investments as of fiscal 2021. There were $1.09B in debt and $546.50M in liabilities at the time. Its Book Value Per Share was $26.25, while its Total Shareholder’s Equity was $4.27B.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BMRN is Buy with a score of 4.36.

Most Popular

Related Posts